The Benefit of Radiotherapy/Antiandrogen Combination in Men With Locally Advanced Prostate Cancer

Video

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, comments on the benefit of radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

Clinical Pearls

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, comments on the benefit of radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

  • The primary aim of this study was to show a 10% reduction in prostate cancer mortality
  • The final analysis (median follow-up of 11 years) showed about an 11% reduction in prostate cancer-specific mortality
  • The benefit could have been even greater, as elderly men die of other causes which cannot be affected by treatment, such as cardiovascular disease
Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content